Rights and permissions
About this article
Cite this article
Natalizumab may be cost effective for MS in Norway. Inpharma Wkly. 1616, 4 (2007). https://doi.org/10.2165/00128413-200716160-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200716160-00006